|Slideshows|May 18, 2017

7 Medical Illnesses That May Present as Anxiety

Author(s)Yu Dong, MD, PhD, Fatima Noorani, MD, Rushi Vyas, MD

Beyond psychosocial implications of anxiety disorders, an array of physiological effects may ensue.

To view a PDF, of this slideshow, click here.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

ByJessica Walters

October 23rd 2025

LSD for Generalized Anxiety Disorder: New Findings Review With Maurizio Fava, MD

ByMaurizio Fava, MD

October 8th 2025

SYT-510: First-in-Class Inhibitor Targets Endocannabinoid System to Improve Mental Health Outcomes

ByLeah Kuntz

September 24th 2025

lumateprone caplyta major depressive disorder anxious distress

Phase 3 Study of Lumateperone as Adjunct to Antidepressant Therapy for Major Depressive Disorder and Anxious Distress Meets End Points

ByJessica Walters

September 21st 2025

Childhood-Onset Fluency Disorder: Perspectives on Comorbid Anxiety and Stuttering

ByYoshikazu Kikuchi, MD, PhD,Heidi Anne Duerr, MPH

September 17th 2025

Latest CME

Video

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

7 Medical Illnesses That May Present as Anxiety

Newsletter

Related Content

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

LSD for Generalized Anxiety Disorder: New Findings Review With Maurizio Fava, MD

SYT-510: First-in-Class Inhibitor Targets Endocannabinoid System to Improve Mental Health Outcomes

Phase 3 Study of Lumateperone as Adjunct to Antidepressant Therapy for Major Depressive Disorder and Anxious Distress Meets End Points

Childhood-Onset Fluency Disorder: Perspectives on Comorbid Anxiety and Stuttering

Latest CME

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Approves Caplyta for Adjunctive Treatment of Major Depressive Disorder

Bridging the Categorical-Dimensional Divide: Exploring the PRiSM Diagnostic Instrument

Sex Differences and Lifestyle Changes in ADHD

The Spiritual Determinants of Health and Mental Health

Caplyta FDA Approval: Benefits for Patients, With Roger McIntyre, MD